期刊
BRITISH JOURNAL OF HAEMATOLOGY
卷 147, 期 1, 页码 89-96出版社
WILEY
DOI: 10.1111/j.1365-2141.2009.07836.x
关键词
non-Hodgkin lymphoma; bortezomib; proteasome; fludarabine; rituximab
类别
资金
- National Institutes of Health [CA62502]
- Case Western Reserve University
- University Hospitals Case Medical Center [P30 CA43703]
- Case GCRC [M01RR00080]
P>Based on the hypothesis that bortezomib may potentiate fludarabine activity by inhibiting DNA repair, we designed a phase I trial using this combination with rituximab in patients with relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma. Twenty-four patients were enrolled. Non-Hodgkin lymphoma subtypes included 12 patients with follicular lymphoma, four with marginal zone lymphoma, three with lymphoplasmacytic lymphoma, three with mantle cell lymphoma and two with small lymphocytic/chronic lymphocytic leukaemia. Fludarabine and bortezomib were escalated in cohorts of three patients. Rituximab was added to the maximum tolerated dose of fludarabine and bortezomib and added significant dose-limiting myelosuppression. The maximum tolerated dose was fludarabine 25 mg/m
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据